Healthy Hepper.com Bi-Monthly Liver Newsletter
October 28, 2009
Here is the latest news and research on Hepatitis C:
There are two protease inhibitors that could offer a much-needed new option in HCV treatment, which is why they take center-stage at every major medical meeting where HCV is on the agenda. These are Phase III drugs- Vertex Pharmaceuticals` telaprevir and Schering-Plough's boceprevir. Analysts also are watching competing protease inhibitors like Schering's SCH-900518, Boehringer Ingelheim's BI-201335 and Tibotec's TMC-435350.
For now, the protease inhibitors are being studied as add-ons to ribavirin and interferon, but experts are eager for ways to reduce or eliminate reliance on the standard of care. One such approach, which combined a protease inhibitor with a polymerase inhibitor, made a huge splash at another liver meeting this spring, and updated data are coming at AASLD which is being held in Boston Oct.30-Nov.3.
Hepatitis C Personal Stories
New Webpage created for sharing personal experiences with the Hep C virus.
SciClone Announces Enrollment of First Patient in Its Phase 2 Trial of SCV-07 in Hepatitis C
SciClone is eager to investigate further SCV-07's potential to enhance the immune response against hepatitis C and to determine whether the compound is capable of improving the current standard of care treatment.
New Book, 'Breaking Free from Hepatitis C: A Personal Journey'
Personal account, based on author's journal and experience over the course of 11 years, offers insider's look and calls for action on prevention.
interview with author at
Lots of coffee may be good for people with hepatitis C
A study of people infected with the liver-damaging virus hepatitis C found the risk of serious liver damage halved in people who drank at least three cups of coffee a day.
Hepatitis C and Alcohol
Is it okay to have an occasional drink if you have Hepatitis C?
Human Genome Sciences gets milestone payment for development of hepatitis C drug, Zalbin
Human Genome Sciences Inc. said Monday it will be paid $75 million by Swiss drugmaker Novartis AG for successful clinical testing of the hepatitis C drug candidate Zalbin. The companies plan to file for U.S. and European regulatory approval in the fourth quarter. Assuming licensure by the FDA and other regulatory agencies, HGS believes that ZALBIN could become a market-leading treatment for chronic hepatitis C.
Hepatitis C Associated Skin Conditions
Review of Hep C associated skin problems by the Society of Correctional Physicians (SCP).
Liver stiffness scan shows cirrhosis
Fibroscan is a quick and reliable noninvasive technique that can be applied successfully in the vast majority of patients to estimate liver fibrosis. The commonest indication for Fibroscan is chronic hepatitis C.
Aethlon Medical Announces BIOCOM Conference Presentation
Hemopurifier® represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier® seeks to improve Hepatitis-C treatment outcomes.
Wishing you health,